AveDuration by stage for HSV-2 (M then F)
2.6		544.6	1.1	
2.6		544.6	1.1
AveDuration by stage for syphilis (M then F)
4.4		6.09	14.9	572.3	23.0	51.5
4.4		6.09	14.9	572.3	23.0	51.5
AveDuration by stage for chancroid (M then F)
8.7		8.7		52.0
8.7		8.7		52.0
AveDuration by stage for gonorrhoea (M then F)
17.8	17.8	68.2
14.8	14.8	68.2
AveDuration by stage for chlamydia (M then F)
17.0	89.1	489.9
17.0	89.1	489.9
AveDuration by stage for trichomoniasis (M then F)
2.02	21.2	62.8
14.9	157.3	62.8
AveDuration by stage for HIV (M then F)1560.0
13.0	268.0	215.0	102.0	1560.0
13.0	268.0	215.0	102.0	1560.0
AveDuration by stage for VC
28.9	12.0
CtsTransition into BV state 1 (from states 2, 3 & 4)
0.0644	0.0075	0.0075
CtsTransition into BV state 2 (from states 1, 3 & 4)
0.0349	0.0442	0.0442
Annualized RecurrenceRate (HSV-2 M & F, VC) [default value for VC is 0.53]
6.17	3.06	0.448
PropnImmuneAfterRx (HD, NG, CT, TV; M then F)
0.0		0.0		0.723	0.0
0.0		0.0		0.723	0.0
PropnImmuneAfterSR (HD, NG, CT, TV; M then F)
1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0
SymptomaticPropn (HSV-2, HD, NG, CT, TV, BV; M then F)
0.177	0.90	0.877	0.326	0.385
0.177	0.70	0.348	0.168	0.285	0.221
TransmProb (HSV-2, TP, HD, NG, CT, TV; M then F then client-to-sex worker)
0.0083	0.174	0.20	0.456	0.176	0.222
0.0029	0.195	0.20	0.223	0.111	0.047
0.0018	0.174	0.20	0.456	0.176	0.222
RelTransmLT (HSV-2, TP, HD, NG, CT, TV, HIV; M then F)
0.108	1.00	1.00	1.00	1.00	1.00	1.00
0.053	1.00	1.00	1.00	1.00	1.00	1.00
TransmProb[] for HIV (CSW-client, ST rel, LT rel high, LT rel low; M then F)
0.003000	0.008341	0.001960
0.003623	0.003623	0.001747
CondomEff (HSV-2, TP, HD, NG, CT, TV, HIV, HPV; M then F)
0.75	0.9		0.9		0.9		0.9		0.9		0.9		
0.75	0.9		0.9		0.9		0.9		0.9		0.9		
Condom Eff HPV
0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
HIVinfecIncrease for HSV-2 (M then F)
1.4		0.1		1.4		0.1
1.4		0.1		1.4		0.1
HIVinfecIncrease for TP (M then F)
0.3		1.4		0.3		0.0		0.0		0.0
0.3		1.4		0.3		0.0		0.0		0.0
HIVinfecIncrease for HD (M then F)
1.4		0.0
1.4		0.0
HIVinfecIncrease for NG (M then F)
2.1		2.1
0.8		0.8
HIVinfecIncrease for CT (M then F)
0.8		0.8
0.8		0.0
HIVinfecIncrease for TV (M then F)
0.0		0.0
0.0		0.0
HIVinfecIncrease for HIV (M then F) -0.5
18.539		0.0		2.626		5.895		-0.5		2.626
18.539		0.0		2.626		5.895		-0.5		2.626
HIVinfecIncrease for VC
0.8		0.8
HIVinfecIncrease for BV
0.0		0.0		0.0
HIVsuscepIncrease for HSV-2 (M then F)
2.8		1.3		2.8		1.3
2.8		1.3		2.8		1.3
HIVsuscepIncrease for TP (M then F)
1.4		2.8		1.4		0.0		0.0		0.0
1.4		2.8		1.4		0.0		0.0		0.0
HIVsuscepIncrease for HD (M then F)
2.8		1.4
2.8		1.4
HIVsuscepIncrease for NG (M then F)
2.4		2.4
2.4		2.4
HIVsuscepIncrease for CT (M then F)
1.9		1.9
1.9		1.9
HIVsuscepIncrease for TV (M then F)
1.0		1.0
1.0		1.0
HIVsuscepIncrease for VC
1.7		1.7
HIVsuscepIncrease for BV
0.0		0.4		0.4
SuscepIncrease in males (HSV-2, TP, HD, NG, CT, TV, HIV)
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
SuscepIncrease in females (HSV-2, TP, HD, NG, CT, TV, HIV)
1.0		1.0		1.0		1.0		2.5		1.0		2.5
1.0		1.0		1.0		1.0		2.5		1.0		2.5
1.0		1.0		1.0		1.0		1.5		1.0		1.5
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
1.0		1.0		1.0		1.0		1.0		1.0		1.0
Herpes SheddingIncrease[5]
1.0		1.0		1.0		1.0		1.0
Herpes RecurrenceIncrease[5]
1.0		1.0		2.0		3.0		1.0
VC IncidenceIncrease[5]
0.0		0.0		0.5		1.0		0.0
Annual incidence of VC (15-19) and weekly incidence of BV (1 partner)
0.942	0.117
BV IncidenceMultTwoPartners, IncidenceMultNoPartners
1.0		0.5
Herpes SymptomInfecIncrease
17.4
InfecIncreaseSyndrome[][] (GUD, discharge, asymp STD; M then F)
0.9		0.8		0.1
0.9		0.3		0.1
SuscepIncreaseSyndrome[][] (GUD, discharge, asymp STD; M then F)
1.1		0.6		0.4
0.7		0.3		0.2
RelHIVfertility, by HIV stage
1.00	0.92	0.80	0.73	1.20	0.80
PropnInfectedAtBirth, PropnInfectedAfterBirth
0.20	0.16
Median time to AIDS in kids infected at birth (M, F) and after birth (M, F)
0.50	0.50	7.80	7.80
Weibull shape for time to AIDS in kids infected at birth (M, F) and after birth (M, F)
0.70	0.70	5.50	5.50
Mean survival after AIDS, in kids infected at birth (M, F) and after birth (M, F)
0.43	0.43	1.34	1.34
MaleTeenRxRate, MaleRxRate, FemTeenRxRate, FemRxRate, FSWRxRate
0.23	0.57	0.12	0.23	0.90
PropnTreatedPublicM, PropnTreatedPublicF, PropnTreatedPrivateM, PropnTreatedPrivateF
0.45	0.60	0.40	0.30
CorrectRxPreSM (HSV-2, TP, HD, NG, CT, TV, BV, VC)
0.0		0.763	0.50	0.710	0.711	0.409	0.400	0.479
CorrectRxWithSM (HSV-2, TP, HD, NG, CT, TV, BV; M then F)
0.00	1.00	1.00	1.00	1.00	0.50
0.00	1.00	1.00	1.00	1.00	1.00	1.00
DrugEff (HSV-2, TP, HD, NG, CT, TV, BV, VC)
0.90	0.90	0.90	0.90	0.90	0.90	0.60	0.55
DrugPartialEff (BV, VC)
0.20	0.30
TradnalEff (HSV-2, TP, HD, NG, CT, TV, BV, VC)
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Syphilis: ANCpropnScreened, ANCpropnTreated
0.75	0.80
HIV: AcceptScreening, AcceptNVP, RednNVP, RednFF
0.80	1.00	0.47	0.50
Syphilis: SecondaryRxMult, SecondaryCureMult, PropnSuscepAfterRx (M then F)
0.30	0.30	0.419	0.419
FSWasympRxRate, FSWasympCure
0.08	0.5
InitHIVprevFSW (use 0.00 for 'no AIDS' scenario, 0.001827 for 1985, 0.02168 for 1990) 
0.00
RatioUltToInitHIVtransm
1.00
SDsuscepHIVadj
0.5
Vaccine efficacy (bi) 1.00	1.00	0.50	0.50	0.00	0.00	0.50	0.00	0.00	0.00	0.00	0.00	0.00
1.00	1.00	0.50	0.50	0.00	0.00	0.50	0.00	0.00	0.00	0.00	0.00	0.00
Proportion vaccinated in WHO project (PropVaccinatedWHO)
0.9
Proportion HIV+ vaccinated in WHO project (PropVaccinatedHIV)
0.5
Vaccine efficacy (nona) 
1.00	1.00	1.00	1.00	0.00	0.00	1.00	0.00	1.00	0.00	1.00	0.00	0.00
Parameters in this model are the posterior MEANS for the STI parameters and the
averages of the 100 HIV parameter combinations providing best fit to the HIV data.